Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Vasculitis syndromes

Tocilizumab — a new frontier for GCA therapy

Nature Reviews Rheumatology volume 13, pages 700–701 (2017)Cite this article

Subjects

An unmet need exists for effective glucocorticoid-sparing agents for the treatment of giant cell arteritis (GCA). Tocilizumab, the first intervention to demonstrate substantial therapeutic benefits for patients with newly diagnosed or relapsing GCA, is changing the landscape of treatment and ushering in a new era of biologic therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Mahr, A. D. et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 56, 2789–2797 (2007).

    Article  CAS  Google Scholar 

  2. Stone, J. H. et al. Trial of tocilizumab in giant-cell arteritis. N. Engl. J. Med. 377, 317–328 (2017).

    Article  CAS  Google Scholar 

  3. Villiger, P. M. et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase II, randomised, double-blind, placebo-controlled trial. Lancet 387, 1921–1927 (2016).

    Article  CAS  Google Scholar 

  4. Koster, M. J., Matteson, E. L. & Warrington, K. J. Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis. Curr. Opin. Rheumatol 28, 211–217 (2016).

    Article  Google Scholar 

  5. Tuckwell, K. et al. Newly diagnosed versus relapsing giant cell arteritis: baseline data from the GiACTA trial. Semin. Arthritis Rheum. 46, 657–664 (2017).

    Article  Google Scholar 

  6. Unizony, S. et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res. (Hoboken) 64, 1720–1729 (2012).

    Article  CAS  Google Scholar 

  7. Garcia-Martinez, A. et al. Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). Ann. Rheum. Dis. 73, 1826–1832 (2014).

    Article  Google Scholar 

  8. Maleszewski, J. J. et al. Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. Mod. Pathol. 30, 788–796 (2017).

    Article  CAS  Google Scholar 

  9. Weyand, C. M. & Goronzy, J. J. Immune mechanisms in medium and large-vessel vasculitis. Nat. Rev. Rheumatol 9, 731–740 (2013).

    Article  CAS  Google Scholar 

  10. Langford, C. A. et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 69, 837–845 (2017).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Matthew J. Koster and Kenneth J. Warrington are at Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.,

    Matthew J. Koster & Kenneth J. Warrington

Authors
  1. Matthew J. Koster
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth J. Warrington
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth J. Warrington.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koster, M., Warrington, K. Tocilizumab — a new frontier for GCA therapy. Nat Rev Rheumatol 13, 700–701 (2017). https://doi.org/10.1038/nrrheum.2017.150

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2017.150

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing